Indaptus Therapeutics Stock Current Valuation
| INDP Stock | USD 8.16 0.82 9.13% |
Valuation analysis of Indaptus Therapeutics helps investors to measure Indaptus Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 08/01/2025, Enterprise Value Over EBITDA is likely to drop to -0.15. In addition to that, Enterprise Value Multiple is likely to drop to -0.15. Fundamental drivers impacting Indaptus Therapeutics' valuation include:
Overvalued
Today
Please note that Indaptus Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Indaptus Therapeutics is based on 3 months time horizon. Increasing Indaptus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Indaptus Therapeutics' intrinsic value may or may not be the same as its current market price of 8.16, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.16 | Real 5.0 | Target 2.0 | Hype 8.35 | Naive 7.71 |
The intrinsic value of Indaptus Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Indaptus Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Indaptus Therapeutics helps investors to forecast how Indaptus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Indaptus Therapeutics more accurately as focusing exclusively on Indaptus Therapeutics' fundamentals will not take into account other important factors: Indaptus Therapeutics Company Current Valuation Analysis
Indaptus Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Indaptus Therapeutics Current Valuation | 841.38 K |
Most of Indaptus Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Indaptus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Indaptus Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Indaptus Therapeutics is extremely important. It helps to project a fair market value of Indaptus Stock properly, considering its historical fundamentals such as Current Valuation. Since Indaptus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Indaptus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Indaptus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Indaptus Therapeutics has a Current Valuation of 841.38 K. This is 99.99% lower than that of the Biotechnology sector and 99.98% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Indaptus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Indaptus Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Indaptus Therapeutics could also be used in its relative valuation, which is a method of valuing Indaptus Therapeutics by comparing valuation metrics of similar companies.Indaptus Therapeutics is currently under evaluation in current valuation category among its peers.
Indaptus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Indaptus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Indaptus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Indaptus Fundamentals
| Return On Equity | -2.59 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 841.38 K | ||||
| Shares Outstanding | 572.66 K | ||||
| Shares Owned By Insiders | 19.42 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 14.72 K | ||||
| Price To Book | 1.67 X | ||||
| EBITDA | (15.02 M) | ||||
| Net Income | (15.02 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 84.16 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 4.89 X | ||||
| Cash Flow From Operations | (12.32 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (41.44) X | ||||
| Target Price | 56.0 | ||||
| Beta | 1.17 | ||||
| Market Capitalization | 4.67 M | ||||
| Total Asset | 7.34 M | ||||
| Retained Earnings | (60.44 M) | ||||
| Working Capital | 3.22 M | ||||
| Net Asset | 7.34 M |
About Indaptus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Indaptus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Indaptus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Indaptus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.